Key result
Despite advances in immunosuppressive therapy, chronic rejection manifesting as cardiac allograft vasculopathy remains a significant limitation in long-term survival after heart transplantation.
This review highlights the immunologic basis of cardiac allograft rejection and emphasizes the need for early noninvasive detection of cardiac allograft vasculopathy to improve long-term outcomes in heart transplant recipients.
CAV persists as a major post-transplant survival barrier; leaves open optimal noninvasive detection strategies pending prospective studies.
Despite long-term complications from chronic immunosuppressive therapy, the phenomenon of chronic rejection is still a limitation in cardiac allograft recipients. In this review, starting from basic immunologic concepts, we analyze the mechanisms involved in rejection following heart transplantation, with particular emphasis on chronic rejection manifested as cardiac allograft vasculopathy (CAV). Etiopathogenesis of CAV and diagnostic imaging studies are also discussed.
No takes yet. Share an insight, caveat, or question.
Savasta et al. (2011) conducted a review in Cardiac allograft rejection and cardiac allograft vasculopathy (CAV). Immunosuppressive therapy was evaluated. Despite advances in immunosuppressive therapy, chronic rejection manifesting as cardiac allograft vasculopathy remains a significant limitation in long-term survival after heart transplantation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: